Skip to main content

Table 1 Patients’ baseline characteristics

From: Nasal high-flow bronchodilator nebulization: a randomized cross-over study

Variable N = 25
Female/male 10 (40%)/15 (60%)
Age (years) 60 (53; 68)
Main respiratory disease
 Asthma 9 (36%)
 COPD 14 (56%)
 Other 2 (8%)
Height (cm) 169 (165; 176)
Weight (kg) 75 (64; 80)
Body mass index (high/weight2) 26 (23; 29)
FEV1 (L) 1.83 (1,38; 2,03)
 Percentage of predicted (%) 60 (53; 71)
FEV1/vital capacity (%) 54 (45; 60)
Functional residual capacity (L) 5,0 (3,9; 6,0)
 Percentage of predicted (%) 150 (139; 171)
Residual volume (L) 4,0 (2,9; 4,4)
 Percentage of predicted (%) 172 (154; 184)
Presence of expiratory flow limitation 6 (24%)
  1. Data are presented as count (percentage) and median (interquartile range)
  2. COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in one second